Boston Scientific Corporation $BSX Stock Holdings Increased by SBI Securities Co. Ltd.

SBI Securities Co. Ltd. boosted its holdings in Boston Scientific Corporation (NYSE:BSX) by 31.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 4,028 shares of the medical equipment provider’s stock after buying an additional 965 shares during the quarter. SBI Securities Co. Ltd.’s holdings in Boston Scientific were worth $433,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. GAMMA Investing LLC raised its stake in shares of Boston Scientific by 15.4% in the second quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock valued at $3,167,000 after purchasing an additional 3,932 shares in the last quarter. MRA Advisory Group acquired a new stake in Boston Scientific during the second quarter worth $273,000. Bank of New Hampshire increased its holdings in Boston Scientific by 552.0% in the 2nd quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock valued at $2,119,000 after buying an additional 16,699 shares during the period. NS Partners Ltd raised its stake in shares of Boston Scientific by 1.6% in the 1st quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock valued at $37,143,000 after buying an additional 5,704 shares in the last quarter. Finally, New England Research & Management Inc. bought a new position in shares of Boston Scientific during the 2nd quarter worth about $1,133,000. Institutional investors own 89.07% of the company’s stock.

Insider Activity

In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the sale, the director owned 24,134 shares of the company’s stock, valued at $2,371,889.52. This represents a 34.82% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at approximately $17,561,336.74. This represents a 21.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 175,782 shares of company stock worth $17,742,314. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Stock Down 2.1%

NYSE BSX opened at $102.73 on Friday. The stock’s 50 day simple moving average is $99.72 and its 200 day simple moving average is $102.56. Boston Scientific Corporation has a one year low of $85.98 and a one year high of $109.50. The firm has a market cap of $152.30 billion, a PE ratio of 54.94, a price-to-earnings-growth ratio of 2.02 and a beta of 0.58. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.04. The firm had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The business’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, sell-side analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on BSX shares. Barclays lifted their target price on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. The Goldman Sachs Group reaffirmed a “buy” rating and set a $124.00 price objective on shares of Boston Scientific in a report on Wednesday, October 22nd. Wells Fargo & Company upped their price objective on Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Canaccord Genuity Group reissued a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a report on Thursday, October 23rd. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $125.00 price target on shares of Boston Scientific in a research note on Monday, September 29th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Boston Scientific has a consensus rating of “Buy” and an average target price of $123.77.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.